CRYOPORT INC. DL-,01

Cryoport reported Q1 FY2026 revenue of $47.8 million and organic growth of 16%, leading it to raise its full-year guidance to $192–196 million. Adjusted EBITDA improved to -$0.6 million despite a loss per share of $0.25 and a net loss of $10.5 million. Growth was driven by Life Sciences Services and Products, particularly BioServices, BioStorage and commercial cell and gene therapies; the company holds $403.6 million in liquid assets. Cryoport emphasizes operational efficiency and expansion of global sites and cites a growing pipeline of clinical trials and commercial approvals as drivers for further revenue growth. » More on de.investing.com

Cryoport reported revenue of $45.45 million for Q4 2025, surpassing expectations by 5.87%, driven by strong demand in commercial cell and gene therapies. Earnings per share were -$0.27, missing the forecast of -$0.21 and indicating persistent profitability challenges. Gross margin improved to 47% thanks to cost-reduction measures, and the stock rose 6.46% in after-hours trading. For 2026, Cryoport forecasts revenue between $190 million and $194 million and emphasizes expanding infrastructure and services to support further growth. » More on de.investing.com

Cryoport generated revenue of $176.2 million in fiscal 2025 (+12% organic) and increased gross margin by 271 basis points to 47%. The adjusted EBITDA deficit narrowed to $5.8 million; Q4 revenue was $45.45 million, driven by the Life Sciences Services segment. The company supports 760 active clinical CGT studies (about 70% market share) and expects 2026 revenue of $190–194 million and positive adjusted EBITDA in early 2026. Risks remain, including a $185 million convertible bond maturing in December 2026 and dependencies on trial progress and regulatory developments. » More on de.investing.com